Biotech Analysts, along with Key Opinion Leader Dr. Gulamhusein of the TorontoCenter for Liver Disease and University Health Networ, discuss management of Primarily Biliary Cholangitis (PBC), along with the up-to-date development landscape, including ursodeoxycholic acid, obeticholic acid, elafibranor, and, relevant to CymaBay, seladelpar on an Analyst/Industry conference call to be held on August 8 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- Is CBAY a Buy, Before Earnings?
- William Blair biotech analysts to hold an analyst/industry conference call
- 3 Best Stocks to Buy Now, 8/1/2023, According to Top Analysts
- CymaBay price target raised to $19 from $12 at H.C. Wainwright
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
